Laboratory Diagnosis of Resistance to Activated Protein C (APC-resistance)

• References

• 1 Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. J Biol Chem 1977; 16: 5824-5831
• 2 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880
• 3 Fay Ph J. Factor VIII structure and function. Throm Haemostas 1993; 70: 63-67
• 4 Walker FJ. Regulation of activated protein C by protein S, the role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-11131
• 5 Bakker HM, Tans G, Janssen Claessen T, Thomassen MC, Hemker HC, Griffin JH, Rosing J. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208: 171-178
• 6 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 1988; 263: 14884-14890
• 7 Koedam JA, Meyers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1243
• 8 Shen L, Dahlbäck B. Factor V and protein S are synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738
• 9 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 10 Koster T, Rosendaal FR, de Ronde H, Briët E, Vanderbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
• 11 Griffin JH, Evatt B, Wideman G, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
• 12 Svenson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 13 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 14 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V^R506Q . J Biol Chem 1995; 270: 4053-4057
• 15 Nicolaes GAF, Tans G, Christella M, Thomassen LGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va^R506Qby activated protein C. J Biol Chem 1995; 270: 21158-21166
• 16 Aparicio G, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg⁵⁰⁶to Gln mutation in the factor V gene. Biochem J 1996; 313: 467-472
• 17 Heeb MJ, Kojima Y, Greengard JS, & Griffin JH. Activated protein C resistance: molecular mechanism based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-3411
• 18 Denson KWE, Reed SV, Haddon ME. The modified APC-resistance test. Thromb Haemostas 1995; 74: 995
• 19 Gilmore G, Thom J, Baker RI. Diagnosis of APC-resistance in patients on standard or low molecular weight heparin. Thromb Haemostas 1996; 75: 372-373
• 20 Trossaert M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC-resistance test in the presence of factor V deficient plasma, can be used in patients without oral anticoagulant. Thromb Heamostas 1996; 75: 521-522
• 21 Ahlenc-Gelas M, Aillaud MF, Bonvarlet MN, Dupuy G, Juhan-Vague I, Aiach M. Specificity of an assay based on a factor V- depleted plasma in patients carrying the Arg 506 Gin mutation. Thromb Heamostas 1996; 75: 971-977
• 22 Tosetto A, Rodeghiero F. Diagnosis of the APC-resistance in patients on oral anticoagulant therapy. Thromb Heamostas 1995; 73: 732-733
• 23 Cadroy Y, Sié P, Ahlenc-Gelas M, Aiach M. Evaluation of APC-resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemostas 1995; 73: 734-735
• 24 Colucci M, Ciavarella N, Giliberti MG, Semararo W. Resistance to activated protein C (APC): influence of factor V levels. Thromb Haemostas 1994; 72: 987-988
• 25 Jorquera JI, Aznar J, Fernandez MA, Montoro JM, Curats R, Casaña P. A modification of the APC-resistance test and its application to the study of patients on coumarin therapy. Thromb Res 1996; 82: 217-224
• 26 Varadi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE, Keil B, Schwarz HP. A chromogenic assay for activated protein C resistance. Br J Haemat 1995; 90: 884-889
• 27 Le DT, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85: 1704-1711
• 28 Kapiotis S, Quehenberger P, Jilma B, Handler S, Pabinger Fashing I, Mannhalter C, Speiser W. Improved characteristics of APC-resistance assay coatest APC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol 1996; 106: 588-593
• 29 Liebman HA, Sutherland D, Bacon R, McGehee W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996; 95: 550-553
• 30 Riewald M, Hintz G, Ritter M, Schmidt M, Neubauer A, Riess H. High sensitivity and specificity of a coagulation assay for the detection of heterozygous and homozygous factor V Leiden based resistance to activated protein C. Blood 1996; 88: 4398-4399
• 31 Preda L, Simioni P, Legnani C, Palareti G, Poggio M, Rossi E, Girolami A. A new global test for the evaluation of the protein C protein S system. Blood Coagul Fibrinolysis 1996; 07: 465-469
• 32 Kraus M, Noah M, Fickensher K. The PCAT. A simple screeing assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-222
• 33 Robert A, Eschwège V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon Contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemostas 1996; 75: 562-566
• 34 Denson KWE, Haddon ME, Reed SV, Davidson S, Littlewood TJ. A more discriminating test for APC-resistance and a possible screeing test to include protein C and protein S. Thromb Res 1996; 81: 151-156
• 35 Kraus M, Wagner C. Evaluation of APC-sensitivty in normal blood donors using different reagents and instruments. Thromb Res 1994; 76: 231-236
• 36 Vasse M, Leduc O, Borg N-Y, Chrétien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res 1994; 76: 47-59
• 37 Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemostas 1994; 72: 255-260
• 38 Ronde deH, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemostas 1994; 72: 880-886
• 39 De Stefano V, Paciaroni K, Mastrangelo S, Rutella S, Bizzi B, Leone G. Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit. Thromb Haemostas 1996; 75: 752-756
• 40 Trossaert M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemostas 1995; 73: 163-164
• 41 Sidelman J, Gram J, Pederson OD, Jespersen J. Influence of plasma platelets on activated protein C resistance assay. Thromb Haemostas 1995; 993-994
• 42 Freyburger G, Bilhou-Nabera C, Dief S, Javorschi S, Labrouche S, Lerebeller MJ, Boisseau MR. Technical and biological conditions influencing the functional APC-resistance test. Thromb Haemostas 1996; 75: 460-465
• 43 Luddington R, Brown K, Baglin T. Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening. Br J Haematol 1996; 92: 744-746
• 44 Shizuka R, Kauda T, Amagai H, Kobayashi I. False positive activated protein C sensitivity ratio (APC). Sensitivity ratio caused by freezing and by contamination of plasma with platelets. Thromb Res 1995; 78: 189-190
• 45 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 07: 761-765
• 46 Henkens CMA, Bom VJJ, van derMeer J. Lowered APC-sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1198-1199
• 47 Villa P, Aznar J, Jorquera JI, Casaña P. Laboratory diagnosis of APC-resistance in patients with lupus anticoagulant. Thromb Haemostas 1995; 74: 1606-1607
• 48 Martorell JR, Muñoz-Castillo A, Gil JL. False positive activated protein C resistance test due to antiphospholipid antibodies is corrected by platelet extract. Thromb Haemostas 1995; 74: 796-797
• 49 Halbmayer DM, Hanshofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemostas 1994; 72: 645-646
• 50 Ruiz-Argüelles GJ, Garrés-Eisele J, Alarcon-Segovia D, Ruiz-Argtielles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996; 7: 344-348
• 51 Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Broco G, Russo C, Corrocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470
• 52 Østerud B, Robertsen R, Åsvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 1994; 5: 853-854
• 53 Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb and Haemostas 1995; 73: 402-404
• 54 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutationin 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
• 55 Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemostas 1993; 70: 1067-1071
• 56 Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV: Q⁵⁰⁶mutation. Evaluation of thirteen plasma-based methods for their diagnotic efficacy in comparison with DNA-analysis. Thromb Haemostas. 1997 in press
• 57 Hoagland LE, Triplett DA, Peng F, Barna L. APC-resistance as measured by a textarin time assay: comparison to the APTT-based method. Thromb Res 1996; 83: 363-373
• 58 Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Kojima K, Hackeng TM, Greengard JS. Activated protein C resistance : molecular mechanisms. Thromb Haemostas 1995; 74: 444-448
• 59 Denson KWE, Reed SV, Haddon ME. The modified APC-resistance test. Thromb Haemost 1995; 74: 995
• 60 Zehnder JL, and Benson RC. Sensitivity and specificity of the APC-resistance assay in detection of individuals with Factor V Leiden. Am J Clin Pathol 1996; 106: 107-111
• 61 Voelkerding KV, Wu L, Williams EC, Hoffman SM, Sabatini LM, Borcherding WR, Huber S. Factor V R506Q gene mutation analysis by PCR-RFLP: optimation, comparison with functional testing for resistance to activated protein C and establishment of cell line controls. Am J Clin Pathol 1996; 106: 100-106
• 62 Legnani C, Palareti G, Biagi R, Coccheri S, Bernardi F, Rosendaal FR, Reitsma PH, de Ronde H, Bertina RM. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol 1996; 93: 694-699
• 63 Aillaud MF, Succo E, Alessi MC, Gandois JM, Gallian P, Morange P, Juhan-Vague I. Resistance to activated protein C. Diagnostic strategy in a laboratory. Thromb Haemostas 1995; 74: 1197-1207
• 64 Liu XY, Nelson D, Grant C, Morthland V, Goodnight SH, Press RD. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagnostic Molecular Pathology 1995; 04: 191-197
• 65 Jorquera JI, Montoro JM, Angeles Fernandez M, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163
• 66 Trossaërt M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston FA, Lane DA. Modified APC-resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709
• 67 Nicolaes GAF, Christella M, Thomassen LGD, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. A prothrombinase assay for detection of resistance to activated protein C. Thromb Haemostas 1996; 76: 404-410
• 68 Simioni P, Soudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A. “Pseudo Homozygous” Activated Protein C Resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemostas 1996; 75: 422-426
• 69 Reitsma PH, van der Velden PH, Vogels E, van Strijp D, Tacker N, Adriaansen H, van Gemen B. Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a Point mutation associated with APC-resistance. Blood Coagul Fibrinolysis 1996; 07: 659-663
• 70 Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemostas 1995; 74: 449-453
• 71 Fisher M, Fernandez JA, Amerisco SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine⁵⁰⁶d glutamine mutation. Stroke 1996; 27: 1163-1166